ArticleMetabolic brain disease2025
Circ_0049472 downregulation relieves Amyloid-β-induced neuronal injury by modulating PDE4A expression via targeting miR-22-3p in Alzheimer's disease.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-coding RNAs and Mitochondrial Dysfunction in Alzheimer's Disease: A Systematic Review.Molecular neurobiology · 2026Pooled it
- From Transcriptome to Therapy: The ncRNA Revolution in Neurodevelopmental Disorders.Brain sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuronal injury is a common event in the development of Alzheimer's disease (AD). Previous studies have suggested that circular RNAs (circRNAs) are involved in neuronal injury in the pathological progression of AD. However, the potential role of circ_0049472 in the AD process is still unclear. Amyloid-β (Aβ)-treated SK-N-SH and CHP212 cells were used as the cell model of AD in vitro. The expression of circ_0049472, miR-22-3p, and phosphodiesterase 4A (PDE4A) was measured by quantitative real-time PCR (qPCR). Cell viability, proliferation, and apoptosis were estimated by Cell Counting Kit-8 (CCK-8) assay, 5-ethynyl-2'-deoxyuridine (EdU) assay, and flow cytometry assay. Proliferating cell nuclear antigen (PCNA), B-cell lymphoma-2 (bcl-2), Bcl-2 related X protein (bax), cleaved-caspase 3, PDE4A, and Postsynaptic protein-95 (PSD-95) were determined using western blot. Interleukin-1β (IL-1β), IL-6, and tumor necrosis factor α (TNF-α) levels were analyzed using enzyme-linked immunosorbent assay (ELISA). JC-1 assay was utilized to evaluate mitochondrial function. Binding between miR-22-3p and circPLAR1 or PDE4A was predicted and verified using dual-luciferase reporter assay or RNA Immunoprecipitation (RIP) assay. Circ_0049472 and PDE4A were overexpressed in Aβ-treated SK-N-SH and CHP212 cells, and miR-22-3p was reduced. Knockdown of circ_0049472 might abolish Aβ-mediated proliferation inhibition and the promotion of apoptosis and inflammation, mitochondrial dysfunction in SK-N-SH and CHP212 cells. Mechanistically, circ_0049472 is competitively bound to miR-22-3p to elevate its target PDE4A. Circ_0049472 knockdown alleviated Aβ-induced SK-N-SH and CHP212 cell dysfunctions via targeting the miR-22-3p/PDE4A axis, suggesting that circ_0049472 knockdown might protect from neuronal injury in AD.
Indexed as
Identifiers
40879806What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.